Biopharmaceutical company Corium announced that the FDA has approved Adlarity to treat patients with mild, moderate or severe dementia associated with Alzheimer’s disease, according to a press release.
The FDA approved once-weekly use of Adlarity (donepezil, Corium) in 5 mg/day or 10 mg/day formulations. The transdermal patch, which can be placed by a patient or caregiver on a patient’s back, thigh or buttocks, delivers a consistent dose of donepezil through the skin, resulting in a low likelihood of adverse gastrointestinal side effects associated with oral donepezil. Patients may be